Given the ligand-receptor mismatch found in preterm infants, and the supplementation of endogenous MLT signaling, the combination of EPO and MLT could be a reasonable and indispensable therapeutic strategy for infants with brain injury, as could therapies that support HIF2α. This evidence concerns the gene EPO and brain injury.